Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from January 9, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 9, 2026.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$1,060.00 – $1,100.00Entry zone — fair-value band

$1,096.95Published — price the day we called it

$1,250.52Target — the price the thesis aimed for

$1,114.00Peak — highest point inside the window, not a realized return

$955.19Window close — end-of-window price, context only

What happened

Partial

Reached 11% of the predicted growth at its peak, without hitting the target.

Peak price

$1,114.00

peak on February 4, 2026 — not a realized return

Peak gain

+1.6%

peak, from the publication price

Window close

$955.19

end-of-window price, context only

Days to target

—

Window

January 9, 2026 – April 9, 2026

The thesis — published January 9, 2026

Predicted growth

+14%

over the measurement window

Target price

$1,250.52

the price the thesis aimed for

Entry zone

$1,060.00 – $1,100.00

the fair-value band we waited for

Price at publication

$1,096.95

published January 9, 2026

Confidence

79%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly is a high-quality growth company that recently announced multiple drug discovery partnerships using AI. Those deals suggest the company can develop new medicines faster, which helps its growth story even without a big earnings surprise. The stock is holding steady rather than racing higher, so buying small amounts on mild pullbacks is a safer approach than chasing strength.

Primary drivers

New AI partnerships could speed up drug development and boost confidence
Healthcare stocks often hold up better when markets wobble
Strong business and steady demand from diabetes and obesity products
Current sideways action favors buying small dips over chasing rallies

How it played out

LLY: the target was not reached

Lyra published LLY on 2026-01-09 at 1096.95, with expected growth of 14% and a target of 1250.52. The thesis pointed to artificial intelligence drug discovery partnerships, defensive healthcare demand, diabetes and obesity products, and sideways trading that favored small pullbacks over chasing strength.

Inside the window from 2026-01-09 to 2026-04-09, LLY peaked at 1114 on 2026-02-04, a 1.6% gain. It stayed below the target. The stock ended at 955.19. The thesis only partially played out on price, because there was a small early rise, but the target was never reached and the window closed lower.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals